USPTO serial 90812301
ACCRETAMAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 11, 2023
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ACCRETAMAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal Odedra
Kaushal Odedra ODEDRA LAW OFFICE, PLLC2020 PENNSYLVANIA AVE, NW, #152WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids, hormones in the nature of pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticals, namely, corticosteroids for treatment of hypopituitarism, of congenital adrenal hyperplasia, of rheumatoid arthritis, of rheumatic fever, of crohn's disease, and of chronic active hepatitis; pharmaceuticals, namely, estrogen preparations and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents; pharmaceuticals, namely, cataplasms being medical plasters for the treatment of bruises, lumbago and stiff shoulder; pharmaceuticals, namely, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents in the nature of vitamins for treating vitamin deficiencies, anti-coagulants, enzyme preparations for medical purposes for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, charred drugs delivery agents in the form of capsules, liquids, powders, patches for treating peptic ulcers, moxa in the nature of cone or stick made of ground mugwort leaves for treating peptic ulcers; pharmaceuticals, namely, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; pharmaceuticals, namely, germination controllers and plant rearing agents in the nature of herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; pharmaceuticals, namely, antiseptics, pharmaceutical drugs in the nature of drug delivery agents in the form of coatings for tablets for the treatment of arteriosclerosis, oncostatic drugs in the nature of pharmaceutical products for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs in the nature of pharmaceutical products for the prevention and treatment of parkinsonism, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances and nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases; all the foregoing pharmaceuticals and vaccines comprising monoclonal antibodies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 11, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 11, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 25, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 25, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 17, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Mar 10, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Mar 7, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 31, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 31, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 31, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 30, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 29, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 29, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 16, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 16, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 16, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 20, 2021 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Sep 17, 2021 | ALIE | ASSIGNED TO LIE | — |
| Sep 14, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 21, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 9, 2021 | NWAP | NEW APPLICATION ENTERED | — |